Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

• Register: ClinicalTrials.gov
• Last refreshed on: 19 October 2017
• Main ID: NCT00004143
• Date of registration: 10/12/1999
• Prospective Registration: No
• Primary sponsor: David Rizzieri, MD
• Public title: Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
• Scientific title: Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes
• Date of first enrolment: September 1999
• Target sample size: 2
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT00004143
• Study type: Interventional
• Phase: Phase 2

Countries of recruitment

United States

Contacts

• Name: David A. Rizzieri, MD
• Affiliation: Duke Cancer Institute

• Name: Mitchell Horwitz, MD
• Affiliation: Duke University

Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients must have their clinical material reviewed at the transplanting institution
and the diagnosis confirmed

- Performance status must be Cancer and Leukemia Group B (CALGB) Performance Status (PS)
0, 1, or 2.

- Patients must have a 5/6 to 6/6 HLA matched family member donor who is evaluated and
deemed able to provide PBSCs and/or marrow by the transplant team. Donor must have <
50% Hemoglobin S (HgS) on hemoglobin electrophoresis. Cytomegalovirus (CMV) status of
the donor will be assessed, but not used as an exclusion criterion.

- Patients must meet the following laboratory parameters unless due to disease status as
determined by the treating physician:

1. bilirubin and hepatic transaminases and creatinine must be reviewed by the
transplantation center and deemed acceptable.

2. HIV antibody negative.

3. hematocrit, white cell count, platelet counts and hematologic status will be
reviewed by the treating physician before patient is deemed acceptable.

- Patient must agree to use some form of adequate birth control during the periods that
they receive chemotherapy and any post-chemotherapy medications related to the
transplant.

- Patients must also have a resting multiple gated acquisition scan (MUGA) or
echocardiogram and Pulmonary Function Tests (PFTs) with Diffusing Capacity of the Lung
for Carbon Monoxide (DLCO) performed before transplant. Recommended minimum standards
include an Ejection Fraction (EF) greater than 40% and DLCO greater than 40% for this
less toxic regimen.

- Appropriate cardiology or pulmonary consultations should be considered if the patient
has severe cardiac or lung disease at the initiation of therapy.

I) Hemoglobinopathies:

(a)Sickle Cell Anemia having history of one or more of the following despite treatment with
standard therapies such as hydroxyurea: i) 2 or more episodes of acute chest syndrome since
age 13 years ii) pulmonary hypertension as measured by tricuspid regurgitant jet velocity
of greater than 2.5m/s iii) 2 or more painful crisis per year requiring medical care and
analgesia in excess of what is needed at baseline.

iv) history of cerebrovascular accident (b)Thalassemia major: Those eligible will have
either cardiac or hepatic sequela of thalassemia as documented by biopsy or functional
studies. For those with hepatic damage, this would be an increase in size by 50% of the
liver or a doubling of the total bilirubin, aspartate transaminase (AST), alanine
aminotransferase (ALT), or alkaline phosphatase. To be eligible for transplant due to
cardiac damage, there must be evidence of left ventricular dysfunction as measured by MUGA
scan or echocardiography.

II) Bone marrow failure Disorders

1. Severe Aplastic Anemia: Cytopenia consisting of at least 2 of the following 3:
absolute neutrophil count less than 500/µL, platelet count less than 20,000/µL, and
reticulocyte count less than 50,000/µL.

2. Paroxysmal nocturnal hemoglobinuria (PNH): Patients must have a history of either
life-threatening thrombosis, cytopenia, transfusion dependence or recurrent,
debilitating hemolytic crisis

3. Pure red cell aplasia: Patients must be transfusion dependent.

Exclusion Criteria:

- pregnant or lactating women,

- patients with other major medical or psychiatric illnesses which the treating or
transplant physician feels could seriously compromise compliance to this protocol

- patients with known history of allergies to murine protein



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Sickle Cell Anemia

Severe Aplastic Anemia

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Pure Red Cell Aplasia

Intervention(s)

Drug: Campath, Chemo and/or TBI Allo SCT

Primary Outcome(s)

Number of Participants With Grade 3-4 Unexpected Adverse Events [Time Frame: 45 days post transplant]

Number of Participants With Transplant-related Mortality [Time Frame: 100 days]

Number of Patients With Neutrophil Engraftment [Time Frame: 1 year post transplant]

Number of Patients With Grade 3-4 Acute Graft Versus Host Disease (GVHD) [Time Frame: 60 days post transplant]

Number of Patients With Platelet Engraftment [Time Frame: 1 year post transplant]

Secondary Outcome(s)

Overall Survival [Time Frame: 2 years]

Secondary ID(s)

CDR0000067374

NCI-G99-1617

DUMC-1340-99-7

Pro00008771

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Results

• Results available: Yes
• Date Posted: 11/11/2013
• URL: https://clinicaltrials.gov/ct2/show/results/NCT00004143